Vnitr Lek 2005, 51(7-8):802-808

Phenotype and genotype analysis of hereditary hypofibrinogenaemia and dysfibrinogenaemia

A. Bátorová1,*, D. Horváthová1, P. de Moerloose2, M. Neerman-Arbez3, M. Mistrík1
1 Národné hemofilické centrum Kliniky hematológie a transfuziológie LF UK, Bratislava, Slovenská republika, prednosta doc. MUDr. Martin Mistrík, Ph.D.
2 Division of Angiology and Hemostasis, University Hospital, Ženeva, Švajčiarsko, director prof. Dr. H. Bounameaux
3 Departement of Genetic Medicine and Development, University Medical School, Ženeva, Švajčiarsko, director prof. Dr. Stylianos Antonarakis

Inherited fibrinogen disorders, either quantitative (afibrinogenemia, hypofibrinogenemia) or qualitative (dysfibrinogenemia) represent a rare blood coagulation disorders. Clinical manifestation is variable and the bleeding may paradoxically be associated with the thrombotic events. Recently the function of all components of the complex fibrinogen molecule as well as the molecular basis of fibrinogen disorders were defined. Currently the attention is focused upon the relationship between the clinical phenotype and the type of molecular defect with the aim to predict the clinical picture of disease. The phenotype analysis in 67 patients with inherited hypofibrinogenemia and dysfibrinogenemia registered in the National Registry of Inherited Bleeding Disorders in Bratislava has confirmed a wide variation in bleeding manifestation and unpredictable association of bleeding with the invasive procedures in patients with fibrinogen disorders. Genetic analysis in 24 patients has revealed three heterozygous novel mutations: in hypofibrinogenemia the exon 1 FGG gene mutation (Trp3→Stop) and exon 7 FGG gene mutations (Trp253→Cys), in dysfibrinogenemia the exon 2 FGA gene mutation (Aα Gly13→Glu). The results of our study, although limited, suggest an importance of the mutation identification in patients with inherited disorders of fibrinogen. However, further studies are needed to improve the predictive value of the mutational type for the clinical phenotype in particular patient.

Keywords: hypofibrinogenemia; dysfibrinogenemia; bleeding; thrombosis; gene mutations

Received: April 18, 2005; Accepted: April 18, 2005; Published: July 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bátorová A, Horváthová D, de Moerloose P, Neerman-Arbez M, Mistrík M. Phenotype and genotype analysis of hereditary hypofibrinogenaemia and dysfibrinogenaemia. Vnitr Lek. 2005;51(7-8):802-808.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rabe F, Salomon E. Ueber-faserstoffmangel im Blute bei einem Falle von Haemophilie. Arch Klin Med 1920; 95: 2-14.
    2. Risak E. Die Fibrinopenie. Ztsch Klin Med 1935; 128: 605-629.
    3. Mammen EF, Prasad AS, Barnhart M et al. Congenital dysfibrinogenemia: fibrinogen Detroit. J Clin Invest 1969; 48: 235-249. Go to original source... Go to PubMed...
    4. Bolton-Maggs PHB, Perry DJ, Chalmers EA et al. Guidelines. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctor's Organization. Haemophilia 2004; 10: 593-628. Go to original source... Go to PubMed...
    5. Lak M, Keihani M, Elahi F at al. Bleeding and thrombosis in 55 patients with inherited afibrinogenemia. Br J Haematol 1999; 107: 204-206. Go to original source... Go to PubMed...
    6. Fried K, Kaufmann S. Congenital afibrinogenemia in 10 of spring of uncle-niece marriages. Clin Genet 1980; 17: 223-227. Go to original source... Go to PubMed...
    7. Doolittle RF. X-ray crystallographic studies in fibrinogen and fibrin. J Thromb Haemost 2003; 1: 1559-1565. Go to original source... Go to PubMed...
    8. Roberts HR, Monroe DM, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In: Beutler E et al (eds). Williams Haematology. 6th ed. New York - Chicago: The McGraw-Hill Comp, Inc. 2001: 1409-1434.
    9. Matsuda M, Sugo T, Yoshida N et al. Structure and function of fibrinogen: Insights from dysfibrinogens. Thromb Haemost 1999; 82: 283-290. Go to original source... Go to PubMed...
    10. Henselmans JM, Meijer K, Haaxma R et al. Recurrent spontaneous intracerebral heamorrhage in a congenital afibrinogenemic patient: diagnostic pittfals and therapeutic options. Stroke 1999; 30: 2479-2482. Go to original source... Go to PubMed...
    11. Paramaswaran R, Dickinson JP, de Lord S et al. Spontaneous intracranial bleeding in two patients with congenital afibrinogenaemia and the role of replacement therapy. Haemophilia 2000; 6: 705-708. Go to original source... Go to PubMed...
    12. Vu D, Bolton-Maggs HB, Parr JR et al. Congenital afibrinogenemia: identification and expression of a missense mutation in FGB impairing fibrinogen secretion. Blood 2003; 102: 4413-4415. Go to original source... Go to PubMed...
    13. Shima M, Tanaka I, Sawamoto Y et al. Succesful treatment of two brothers with congenital afibrinogenemia for splenic rupture using heat- and solvent detergent-treated fibrinogen concentrates. J Pediatr Hematol Oncol 1997; 19: 462-465. Go to original source... Go to PubMed...
    14. Lefebvre P, Velasco PT, Dear A et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AaIVS4+ 1G>T mutation and an AaGLN328 truncation (fibrinogen Keokuk). Blood 2004; 103: 2571-2576. Go to original source... Go to PubMed...
    15. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151-161. Go to original source... Go to PubMed...
    16. Chafa O, Chellali T, Sternberg C et al. Severe hypofibrinogenemia associated with bilateral ischemic necrosis of toes and fingers. Blood Coag Fibrinol 1995; 6: 549-552. Go to original source... Go to PubMed...
    17. Dupuy F, Soria C, Mohol P et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance toin vivo circulating thrombin. Thromb Res 2001; 102: 211-219. Go to original source... Go to PubMed...
    18. Hamano A, Mimuro J, Aoshima M et al. Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of Ala327Thr: formation of fragile but fibrinolysis-resistant finrin clots and its relevance to arterial thromboembolism. Blood 2004; 103: 3045-3050. Go to original source... Go to PubMed...
    19. Suh TT, Holmback K, Jensen NJ et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-2033. Go to original source... Go to PubMed...
    20. Peyvandi F, Duga S, Akhavan S et al. Rare coagulation disorders. Haemophilia 2002; 8: 308-321. Go to original source... Go to PubMed...
    21. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-619. Go to original source... Go to PubMed...
    22. Neerman-Arbez M, Honsberger A, Antonarakis SE et al. Deletion of fibrinogen (correction of fibrinogen) alphachain gene (FGA) causes congenital afibrinogenemia. J Clin Invest 1999; 103: 215-218. Go to original source... Go to PubMed...
    23. Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90. Go to original source... Go to PubMed...
    24. Neerman-Arbez M, de Moerloose P, Honsberger A et al. Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations inthe FGA and FGG genes. Hum Genet 2001; 108: 237-240. Go to original source... Go to PubMed...
    25. Neerman-Arbez M. The molecular basis of inherited afibrinogenemia. Thromb Haemost 2001; 86: 154-163. Go to original source... Go to PubMed...
    26. Vu D, de Moerloose P, Batorova A et al. Identification and expression of a missense mutation in FGG impairing fibrinogen secretion. J Med Gen; v tlači.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.